Source: Fortune.com
Summary
Sanofi’s CEO, Paul Hudson, discusses the company’s shift from experimenting with AI to operationalizing it in their infrastructure. AI is now used in R&D decisions, supply chain and manufacturing processes, and medicine discovery. Hudson predicts that 2026 will be a tipping point for AI-driven growth, with companies moving from experimentation to enterprise-scale implementation.
Our Reading
The numbers tell one story: Sanofi’s AI-powered transformation is already yielding dramatic results.
AI has shifted from experimentation to becoming a vital part of Sanofi’s infrastructure, powering R&D decisions, supply chain and manufacturing processes, and medicine discovery. The company has discovered 10 new drug targets in just one year, and AI-powered patient recruitment tools have improved clinical trial enrollment rates by 65%. AI-driven tools are also transforming the economics of R&D, reducing costs by an estimated 50%. Sanofi’s supply chain management has enabled the company to avoid $300 million in revenue risk and predict 80% of low inventory risks before they occur.
AI is making drug development not only faster but smarter, with AI agents assessing drug prospects against others in development and assessing opportunity costs. AI is also reshaping the way Sanofi approaches manufacturing,
